CTOs on the Move

Imperative Care

www.imperativecare.com

 
Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Jim Lay
Senior Director Information Technology Profile

Funding

Imperative Care raised $85M on 12/10/2019

Similar Companies

The START Center for Cancer Care

The START Center offers some of the most sophisticated treatment options available in South Texas along with the world’s largest and most active Phase I clinical trials program. The START Center also offers the Inspiritas Spa and Wellness Center whic...

Simcere Pharmaceuticals

Simcere Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spacelabs Healthcare

Spacelabs Healthcare is an American manufacturer of medical equipment and is a wholly owned subsidiary of OSI Systems of Hawthorne, California and offers products and services from three divisions: patient monitoring and connectivity, anesthesia delive...

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.

Virbac

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals` quality of life and to shaping together the future of animal health.